{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,13]],"date-time":"2026-02-13T20:35:44Z","timestamp":1771014944548,"version":"3.50.1"},"reference-count":41,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2011,5,1]],"date-time":"2011-05-01T00:00:00Z","timestamp":1304208000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,11,25]],"date-time":"2019-11-25T00:00:00Z","timestamp":1574640000000},"content-version":"vor","delay-in-days":3130,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"name":"Roche Oy, Finland"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Annals of Oncology"],"published-print":{"date-parts":[[2011,5]]},"DOI":"10.1093\/annonc\/mdq582","type":"journal-article","created":{"date-parts":[[2010,12,7]],"date-time":"2010-12-07T05:49:32Z","timestamp":1291700972000},"page":"1189-1197","source":"Crossref","is-referenced-by-count":35,"title":["Treatment of follicular non-Hodgkin's lymphoma with or without rituximab: cost-effectiveness and value of information based on a 5-year follow-up"],"prefix":"10.1016","volume":"22","author":[{"given":"E.J.O.","family":"Soini","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.A.","family":"Martikainen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"T.","family":"Nousiainen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1093\/annonc\/mdq582_bb0010","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.4065\/80.8.1087","article-title":"Non-Hodgkin lymphoma: diagnosis and treatment","volume":"80","author":"Ansell","year":"2005","journal-title":"Mayo Clin Proc"},{"key":"10.1093\/annonc\/mdq582_bb0015","doi-asserted-by":"crossref","first-page":"657","DOI":"10.2165\/11314820-000000000-00000","article-title":"Economic burden of follicular non-Hodgkin's lymphoma","volume":"27","author":"Foster","year":"2009","journal-title":"Pharmacoeconomics"},{"issue":"17","key":"10.1093\/annonc\/mdq582_bb0020","first-page":"1729","article-title":"Follikulaarisen lymfooman hoito","author":"Jyrkki\u00f6","year":"2007","journal-title":"Finnish Med J"},{"key":"10.1093\/annonc\/mdq582_bb0025","doi-asserted-by":"crossref","first-page":"2215","DOI":"10.1200\/JCO.2005.06.146","article-title":"Meta-analysis to evaluate the role of interferon in follicular lymphoma","volume":"23","author":"Rohatiner","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdq582_bb0030","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1002\/1097-0142(19880201)61:3<441::AID-CNCR2820610306>3.0.CO;2-N","article-title":"Maintenance chlorambucil after CVP in the management of advanced-stage, low-grade histologic type non-Hodgkin's lymphoma. A randomized prospective study with an assessment of prognostic factors","volume":"61","author":"Steward","year":"1998","journal-title":"Cancer"},{"key":"10.1093\/annonc\/mdq582_bb0035","doi-asserted-by":"crossref","first-page":"3295","DOI":"10.1182\/blood-2006-05-021113","article-title":"Rituximab maintenance improves clinical outcome of relapsed\/resistant follicular non-Hodgkin lymphoma in patients both with and without rituximab during induction: results of a prospective randomized phase 3 intergroup trial","volume":"108","author":"van Oers","year":"2006","journal-title":"Blood"},{"key":"10.1093\/annonc\/mdq582_bb0040","doi-asserted-by":"crossref","first-page":"2635","DOI":"10.1182\/blood-2004-03-1110","article-title":"From the bench to the bedside: ways to improve rituximab efficacy","volume":"104","author":"Cartron","year":"2004","journal-title":"Blood"},{"key":"10.1093\/annonc\/mdq582_bb0045","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1182\/blood.V83.2.435.435","article-title":"Depletion of B cells in vivo by a chimeric mouse humanmonoclonal antibody to CD20","volume":"83","author":"Reff","year":"1994","journal-title":"Blood"},{"key":"10.1093\/annonc\/mdq582_bb0050","doi-asserted-by":"crossref","first-page":"4824","DOI":"10.1182\/blood-2008-04-153189","article-title":"Rituximab combined with chemotherapy and interferon in follicular lymphoma patients: results of the GELA-GOELAMS FL2000 study","volume":"112","author":"Salles","year":"2008","journal-title":"Blood"},{"key":"10.1093\/annonc\/mdq582_bb0055","doi-asserted-by":"crossref","first-page":"1986","DOI":"10.1200\/JCO.2006.06.4618","article-title":"Rituximab added to first-line mitoxantrone, chlorambucil, and prednisolone chemotherapy followed by interferon maintenance prolongs survival in patients with advanced follicular lymphoma: an East German Study Group Hematology and Oncology study","volume":"25","author":"Herold","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdq582_bb0060","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1182\/blood-2004-08-3175","article-title":"CVP chemotherapy plus rituximab compared with CVP as first-line treatment for advanced follicular lymphoma","volume":"105","author":"Marcus","year":"2005","journal-title":"Blood"},{"key":"10.1093\/annonc\/mdq582_bb0065","author":"van Oers","year":"2008","journal-title":"Rituximab in remission induction and maintenance treatment of relapsed follicular NHL: a phase III randomized clinical trial. Updated analysis of maintenance"},{"key":"10.1093\/annonc\/mdq582_bb0070","doi-asserted-by":"crossref","first-page":"2853","DOI":"10.1200\/JCO.2009.26.5827","article-title":"Rituximab maintenance treatment of relapsed\/resistant follicular non-Hodgkin's lymphoma: long-term outcome of the EORTC 20981 phase III randomized intergroup study","volume":"28","author":"van Oers","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdq582_bb0075","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1093\/annonc\/mdm543","article-title":"The impact of follicular lymphoma on health-related quality of life","volume":"19","author":"Pettengell","year":"2008","journal-title":"Ann Oncol"},{"key":"10.1093\/annonc\/mdq582_bb0080","series-title":"Finnish Medicine Tariff","author":"FMT","year":"2010"},{"key":"10.1093\/annonc\/mdq582_bb0085","series-title":"Terveydenhuollon yksikk\u00f6kustannukset Suomessa vuonna 2006","author":"Hujanen","year":"2008"},{"key":"10.1093\/annonc\/mdq582_bb0090","series-title":"HYKS-sairaanhoitoalue: Hinnasto","author":"Helsinki University Hospital","year":"2009"},{"key":"10.1093\/annonc\/mdq582_bb0095","doi-asserted-by":"crossref","first-page":"1403","DOI":"10.1007\/s11136-006-0020-1","article-title":"The impact of 29 chronic conditions on health-related quality of life: a general population survey in Finland using 15D and EQ-5D","volume":"15","author":"Saarni","year":"2006","journal-title":"Qual Life Res"},{"key":"10.1093\/annonc\/mdq582_bb0100","series-title":"Decision Modelling for Health Economic Evaluation","author":"Briggs","year":"2006"},{"key":"10.1093\/annonc\/mdq582_bb0105","doi-asserted-by":"crossref","first-page":"S68","DOI":"10.1177\/0272989X98018002S09","article-title":"Net health benefits: a new framework for the analysis of uncertainty in cost-effectiveness analysis","volume":"18","author":"Stinnett","year":"1998","journal-title":"Med Decis Making"},{"key":"10.1093\/annonc\/mdq582_bb0110","doi-asserted-by":"crossref","first-page":"886","DOI":"10.1111\/j.1524-4733.2008.00358.x","article-title":"Optimal cost-effectiveness decisions: the role of the cost-effectiveness acceptability curve (CEAC), the cost-effectiveness acceptability frontier (CEAF), and the expected value of perfection information (EVPI)","volume":"11","author":"Barton","year":"2008","journal-title":"Value Health"},{"key":"10.1093\/annonc\/mdq582_bb0115","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1002\/hec.635","article-title":"Representing uncertainty: the role of cost-effectiveness acceptability curves","volume":"10","author":"Fenwick","year":"2001","journal-title":"Health Econ"},{"key":"10.1093\/annonc\/mdq582_bb0120","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1093\/rheumatology\/kep425","article-title":"Cost-utility of different treatment strategies after the failure of tumour necrosis factor inhibitor in rheumatoid arthritis in the Finnish setting","volume":"49","author":"Hallinen","year":"2010","journal-title":"Rheumatology"},{"key":"10.1093\/annonc\/mdq582_bb0125","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1093\/annonc\/mdq339","article-title":"Trabectedin in the treatment of metastatic soft tissue sarcoma: cost-effectiveness, cost-utility and value of information","volume":"22","author":"Soini","year":"2011","journal-title":"Ann Oncol"},{"key":"10.1093\/annonc\/mdq582_bb0130","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1016\/j.clinthera.2008.02.013","article-title":"Economic evaluation of sunitinib malate in the second line treatment of metastatic renal cell carcinoma (mRCC)\u2014a Bayesian approach","volume":"30","author":"Purmonen","year":"2008","journal-title":"Clin Ther"},{"key":"10.1093\/annonc\/mdq582_bb0135","doi-asserted-by":"crossref","first-page":"803","DOI":"10.2165\/00019053-200523080-00006","article-title":"Economic evaluation of temozolomide in the treatment of recurrent glioblastoma multiforme","volume":"23","author":"Martikainen","year":"2005","journal-title":"Pharmacoeconomics"},{"issue":"Suppl. 5","key":"10.1093\/annonc\/mdq582_bb0140","first-page":"F29","article-title":"Cost-effectiveness of vaccination against cervical cancer: a multi-regional analysis assessing the impact of vaccine characteristics and alternative vaccination scenarios","volume":"26","author":"Suar\u00e9s","year":"2008","journal-title":"Vaccination"},{"key":"10.1093\/annonc\/mdq582_bb0145","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1080\/02841860600965012","volume":"46","author":"Kellokumpu-Lehtinen","year":"2007","journal-title":"Acta Oncol"},{"key":"10.1093\/annonc\/mdq582_bb0150","doi-asserted-by":"crossref","first-page":"284","DOI":"10.3111\/13696998.2010.485951","article-title":"Cost effectiveness of prophylactic HPV 16\/18 vaccination in Finland: results from a modelling exercise","volume":"13","author":"Torvinen","year":"2010","journal-title":"J Med Econ"},{"key":"10.1093\/annonc\/mdq582_bb0155","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1097\/01.mlr.0000170001.10393.b7","article-title":"Common methodological flaws in economic evaluations","volume":"43","author":"Drummond","year":"2005","journal-title":"Med Care"},{"key":"10.1093\/annonc\/mdq582_bb0160","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1111\/j.1600-0609.2004.00368.x","article-title":"Cost-effectiveness of rituximab (MabThera) in diffuse large B-cell lymphoma in The Netherlands","volume":"74","author":"Groot","year":"2005","journal-title":"Eur J Haematol"},{"key":"10.1093\/annonc\/mdq582_bb0165","doi-asserted-by":"crossref","first-page":"35","DOI":"10.2165\/11314070-000000000-00000","article-title":"Cost effectiveness of rituximab maintenance therapy in follicular lymphoma","volume":"28","author":"Deconinck","year":"2010","journal-title":"Pharmacoeconomics"},{"key":"10.1093\/annonc\/mdq582_bb0170","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1080\/02841860802120028","article-title":"Cost-effectiveness of maintenance rituximab treatment after second line therapy in patients with follicular lymphoma in Sweden","volume":"47","author":"Kasteng","year":"2008","journal-title":"Acta Oncol"},{"key":"10.1093\/annonc\/mdq582_bb0175","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1111\/j.1524-4733.2009.00676.x","article-title":"An evaluation of the cost-effectiveness of rituximab in combination with chemotherapy for the first-line treatment of follicular non-Hodgkin's lymphoma in the UK","volume":"13","author":"Ray","year":"2010","journal-title":"Value Health"},{"key":"10.1093\/annonc\/mdq582_bb0180","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1007\/s00277-008-0560-2","article-title":"Quality of life during maintenance therapy with the anti-CD20 antibody rituximab in patients with B cell non-Hodgkin's lymphoma: results of a prospective randomized controlled trial","volume":"88","author":"Witzens-Harig","year":"2009","journal-title":"Ann Hematol"},{"key":"10.1093\/annonc\/mdq582_bb0185","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1093\/jnci\/djn478","article-title":"Rituximab maintenance for the treatment of patients with follicular lymphoma: systematic review and meta-analysis of randomized trials","volume":"101","author":"Vidal","year":"2009","journal-title":"J Natl Cancer Inst"},{"issue":"Suppl. 4","key":"10.1093\/annonc\/mdq582_bb0190","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1093\/annonc\/mdp148","article-title":"Newly diagnosed and relapsed follicular lymphoma: ESMO clinical recommendations for diagnosis, treatment and follow-up","volume":"20","author":"Dreyling","year":"2009","journal-title":"Ann Oncol"},{"key":"10.1093\/annonc\/mdq582_bb0195","series-title":"Reviews of Health Systems","author":"OECD","year":"2005"},{"key":"10.1093\/annonc\/mdq582_bb0200","series-title":"The Finnish Health Care System. A Value-Based Perspective","author":"Teperi","year":"2009"},{"issue":"Suppl 1","key":"10.1093\/annonc\/mdq582_bb0205","doi-asserted-by":"crossref","first-page":"S101","DOI":"10.1002\/hec.1030","article-title":"The impact of changes in Finland's health care system","volume":"14","author":"H\u00e4kkinen","year":"2005","journal-title":"Health Econ"},{"key":"10.1093\/annonc\/mdq582_bb0210","doi-asserted-by":"crossref","first-page":"1957","DOI":"10.1001\/jama.1994.03510480081040","article-title":"Finland's health care system. Universal access to health care in a capitalistic democracy","volume":"271","author":"Hermanson","year":"1994","journal-title":"J Am Med Assoc"}],"container-title":["Annals of Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753419385291?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753419385291?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/academic.oup.com\/annonc\/article-pdf\/22\/5\/1189\/429930\/mdq582.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,6,26]],"date-time":"2021-06-26T09:23:19Z","timestamp":1624699399000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0923753419385291"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,5]]},"references-count":41,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2011,5]]}},"alternative-id":["S0923753419385291"],"URL":"https:\/\/doi.org\/10.1093\/annonc\/mdq582","relation":{},"ISSN":["0923-7534"],"issn-type":[{"value":"0923-7534","type":"print"}],"subject":[],"published":{"date-parts":[[2011,5]]}}}